within Pharmacolibrary.Drugs.ATC.C;

model C01CX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.31666666666666665,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.125,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 12.0
  );

  annotation(Documentation(
    info ="<html><body><p>Xamoterol is a selective Î²1-adrenoceptor partial agonist used for the management of heart failure. It exerts positive inotropic and chronotropic effects while having a mild sympathomimetic activity. It was evaluated primarily in the 1980s and early 1990s for heart failure but is not in current clinical use or approved in most countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li>G J Mulder, K Groen, R B Tijdens, D K Meijer,Pharmacokinetics of xamoterol glucuronidation in the rat in vivo and in liver perfusion.,Xenobiotica; the fate of foreign compounds in biological systems,1987<a href='https://pubmed.ncbi.nlm.nih.gov/2950667/'>https://pubmed.ncbi.nlm.nih.gov/2950667/</a></li><li>W Bastain, M J Boyce, L E Stafford, P B Morton, D A Clarke, H F Marlow,Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers.,European journal of clinical pharmacology,1988<a href='https://pubmed.ncbi.nlm.nih.gov/2904884/'>https://pubmed.ncbi.nlm.nih.gov/2904884/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01CX07;
